Talat Waseem

Dr. Talat Waseem is well known for his research on ghrelin, a hormone involved in homeostasis of feeding behavior. He has discovered anti-inflammatory properties of ghrelin in gastrointestinal tract and suggested that ghrelin might be a future treatment option in management of inflammatory conditions like ulcerative colitis(1). He also points towards the possible role of ghrelin in intestinal adaptation and treatment of short gut syndrome(2). He also has extensively studied the role of ghrelin in gastrointestinal tract cancer(3,4).
He has previously presented his research work at the Annual Meeting of American College of Surgeons in 2004 held at New Orleans(5), Digestive Disease Week-American College of Gastroentrology 2003, and the Society of University Surgeons and International Symposium on Ghrelin (2009).
Waseem graduated from Allama Iqbal Medical College, Lahore, Pakistan and formerly has held a postdoctoral fellow position at Department of Surgery, Brigham & Womens Hospital, Harvard Medical School, Boston.
Research interests
His research interests include ghrelin (1-10, publications), role of ghrelin in gastrointestinal tract (2009 International Symposium on Ghrelin), pancreatic and colorectal cancer(8-10), tissue engineering and robot assisted baraiatic surgery (5,6).
Selected publications
1: Waseem T, Duxbury M, Ito H, Ashley SW, Robinson MK. Exogenous ghrelin
modulates release of pro-inflammatory and anti-inflammatory cytokines in
LPS-stimulated macrophages through distinct signaling pathways. Surgery. 2008
Mar;143(3):334-42. Epub 2007 Dec 27. PubMed PMID: 18291254; PubMed Central PMCID:
PMC2278045.
2: Waseem T. Commentary: Ghrelin's role in gastrointestinal tract cancer. Surg
Oncol. 2009 Mar 25. PubMed PMID: 19324542.
3: Waseem T, Javaid-Ur-Rehman, Ahmad F, Azam M, Qureshi MA. Role of ghrelin axis
in colorectal cancer: a novel association. Peptides. 2008 Aug;29(8):1369-76. Epub
2008 Apr 7. PubMed PMID: 18471933.
4: Waseem T. Technologic advances in Robotic Surgery. J Coll Physicians Surg Pak.
2005 Sep;15(9):559-61. Review. PubMed PMID: 16181577.
5: Waseem T, Mogensen KM, Lautz DB, Robinson MK. Pathophysiology of obesity: why
surgery remains the most effective treatment. Obes Surg. 2007 Oct;17(10):1389-98.
Review. PubMed PMID: 18000735.
6: Javaid-Ur-Rehman, Waseem T. Intestinal tissue engineering: where do we stand?
Surg Today. 2008;38(6):484-6. Epub 2008 May 31. Review. PubMed PMID: 18516525.
7: Waseem T. RNA interference: a potential revolution in disease therapy. J Coll
Physicians Surg Pak. 2006 Jul;16(7):491-2. Review. PubMed PMID: 16827966.
8: Duxbury MS, Ito H, Benoit E, Waseem T, Ashley SW, Whang EE. RNA interference
demonstrates a novel role for integrin-linked kinase as a determinant of
pancreatic adenocarcinoma cell gemcitabine chemoresistance. Clin Cancer Res. 2005
May 1;11(9):3433-8. PubMed PMID: 15867245; PubMed Central PMCID: PMC2734187.
9: Duxbury MS, Waseem T, Ito H, Robinson MK, Zinner MJ, Ashley SW, Whang EE.
Ghrelin promotes pancreatic adenocarcinoma cellular proliferation and
invasiveness. Biochem Biophys Res Commun. 2003 Sep 19;309(2):464-8. PubMed PMID:
12951072.
Publications
His 3 most most cited peer-review articles are
*Duxbury, M.S., Waseem, T., Ito, H., Robinson, M.K., Zinner, M.J., Ashley, S.W., Whang, E.E. "Ghrelin promotes pancreatic adenocarcinoma cellular proliferation and invasiveness" (2003) Biochemical and Biophysical Research Communications, 309 (2), pp. 464-468. Cited 63 times. DOI: 10.1016/j.bbrc.2003.08.024
*Duxbury, M.S., Ito, H., Benoit, E., Waseem, T., Ashley, S.W., Whang, E.E. "A novel role for carcinoembryonic antigen-related cell adhesion molecule 6 as a determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma cells" (2004) Cancer Research, 64 (11), pp. 3987-3993. Cited 29 times. DOI: 10.1158/0008-5472.CAN-04-0424
*Duxbury, M.S., Ito, H., Benoit, E., Waseem, T., Ashley, S.W., Whang, E.E."RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance (2005) Clinical Cancer Research, 11 (9), pp. 3433-3438. Cited 27 times. DOI: 10.1158/1078-0432.CCR-04-1510

Main Menu

See Also

Main Menu